Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hangzhou Qiming Medical Instrument Co., Ltd | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to observe the safety and effectiveness of transcatheter aortic valve replacement in patients with aortic valve stenosis in a real-world clinical practice environment.
This study is a prospective / retrospective, multicenterstudy after listing. The researchers preliminarily confirmed that they could be enrolled in this study according to the diagnosis of the subjects' medical history. After fully informed, they signed the informed consent, and met the TAVR inclusion requirements (see the inclusion criteria for details). At the same time, they registered the subjects in multiple centers. After the start of the trial, the participants were enrolled in the study, All the subjects who met the inclusion criteria but did not meet the discharge criteria were registered in the central registration system. The patients were followed up for 30 days, 6 months and 12 months, and followed up by telephone for 2, 3, 4 and 5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prospective and retrospective study of subjects undergoing aortic valve surgery | Other | This study is a prospective / retrospective, multicenter, and observational study after listing. The researchers can initially determine that they can be enrolled in the study according to the history diagnosis of the subjects. After fully informed, they sign informed consent form. After the evaluation of the researchers, they meet the TAVR selection requirements, and register the subjects in multiple centers at the same time |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| All aortic valve products on the market | Other |
Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data |
| Measure | Description | Time Frame |
|---|---|---|
| Primary end point: the incidence of all-cause death 12 months after operation | After subjects completed aortic valve replacement surgery, whether prospectively or retrospectively, all-cause mortality at 12 months after operation was collected according to the time node of subjects' enrollment | 12 months after aortic valve replacement |
| Measure | Description | Time Frame |
|---|---|---|
| The compound incidence of death, surgery, severe stroke, life-threatening bleeding, serious vascular complications and acute renal failure (within 30 days after operation); | The compound incidence of death, surgery, severe stroke, life-threatening bleeding, serious vascular complications and acute renal failure (within 30 days after operation); | Within 30 days after aortic valve replacement |
Not provided
Inclusion Criteria:
Severe aortic valve stenosis, defined as follows:
Symptomatic patients:
Asymptomatic patients:
Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement
The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;
Be able to contact the subjects or their legal guardians / relatives;
The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)
Note: for dead subjects, they must meet 1, 2 and 5 at the same time before they can be included in the group.
Exclusion Criteria:
Contraindications to any artificial biological valve implantation;
Any known allergies or contraindications;
The patient is currently participating in drug or device research;
The patient is pregnant or lactating;
Aortic annulus diameter < 17 mm or > 32 mm;
The diameter of approach vessel was less than 5.0mm;
The investigator believes that the patient is not suitable to participate in this study or complete the follow-up specified in the protocol;
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41151411 | Derived | Fang Y, Wang H, Li Y, Zhao X, Wang B, Wang G, Liu D, Yan C, Xu K, Han Y. Identification of key diagnostic and prognostic biomarkers for aortic valve stenosis with coronary artery disease through immunological profiling integrating proteomics, single-cell sequencing, and machine learning. Biochem Biophys Res Commun. 2025 Nov 14;789:152855. doi: 10.1016/j.bbrc.2025.152855. Epub 2025 Oct 24. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001024 | Aortic Valve Stenosis |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Retrospective subjects were subjects who had completed transcatheter aortic valve replacement at the beginning of the study. Previous data such as demography and treatment of subjects before the start of the study will be realized by reviewing medical records. Follow up data not traceable to medical records and follow-up data after the start of the study, Prospective subjects were those who were undergoing or planned to undergo transcatheter aortic valve replacement at the beginning of the study. Subjects were enrolled from the beginning of the first case to one year later. The demographic, treatment and follow-up data of subjects will be collected through clinical follow-up or telephone follow-up
Not provided
Not provided
Not provided
Not provided
|
| The implantation rate of permanent pacemaker within 30 days; | The implantation rate of permanent pacemaker within 30 days; | Within 30 days after aortic valve replacement |
| All stroke (disabled or not disabled) within 12 months and 2, 3, 4 and 5 years | All stroke (disabled or not disabled) within 12 months and 2, 3, 4 and 5 years; | 12 months and within 2, 3, 4 and 5 years |
| the incidence of life-threatening bleeding within 12 months and 2, 3, 4 and 5 years; | the incidence of life-threatening bleeding within 12 months and 2, 3, 4 and 5 years; | 12 months and within 2, 3, 4 and 5 years |
| The incidence of reoperation due to dysfunction of prosthetic valve within 12 months and 2,3,4,5 years; | The incidence of reoperation due to dysfunction of prosthetic valve within 12 months and 2,3,4,5 years; | 12 months and within 2, 3, 4 and 5 years |
| The incidence of readmission due to symptoms and signs of aortic valve disease within 12 months and 2,3,4,5 years; | The incidence of readmission due to symptoms and signs of aortic valve disease within 12 months and 2,3,4,5 years; | 12 months and within 2, 3, 4 and 5 years |
| The incidence of prosthetic valve dysfunction at 12 months (moderate or severe stenosis or reflux by ultrasonography); | The incidence of prosthetic valve dysfunction at 12 months (moderate or severe stenosis or reflux by ultrasonography); | 12 months and within 2, 3, 4 and 5 years |
| The incidence of thrombus in clinical and subclinical prosthetic heart valves at 12 months; | The incidence of thrombus in clinical and subclinical prosthetic heart valves at 12 months; | 12 months after aortic valve replacement |
| D014694 |
| Ventricular Outflow Obstruction |